PT  - JOURNAL ARTICLE
AU  - Boltz, Kathy
ED  - Shah, Manisha H.
ED  - Cohen, Ezra E.W.
ED  - Cabanillas, Maria E.
TI  - Targeted and Salvage Therapies Benefit Patients With Thyroid Cancer
DP  - 2015 Jun 18
TA  - MD Conference Express
PG  - 25--26
VI  - 15
IP  - 4
4099  - http://mdc.sagepub.com/content/15/4/25.short
4100  - http://mdc.sagepub.com/content/15/4/25.full
AB  - Sorafenib and lenvatinib can be effective for advanced differentiated thyroid cancer, and vandetanib and cabozantinib can be effective options for advanced medullary thyroid cancer. When first-line tyrosine kinase inhibitors fail for patients, evidence supports salvage therapy for differentiated thyroid cancer but is less compelling for medullary thyroid cancer.